Drugs / PDS01ADC
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04235777 | Jul 2020 → Dec 2027 expected | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04708470 | Oct 2021 → Nov 2026 expected | anus cancer, cervical cancer, human papilloma virus infection, oropharyngeal carcinoma +3 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04633252 | Feb 2021 → Dec 2026 expected | prostate cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04303117 | Jul 2020 → Dec 2028 expected | Kaposi's sarcoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06096870 | Apr 2024 → Dec 2028 expected | prostate carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05361798 | Jun 2023 → Aug 2026 overdue | prostate cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05286814 | Oct 2022 → Dec 2027 expected | adrenal cortex carcinoma, colorectal cancer, intrahepatic cholangiocarcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDS01ADC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05286814 ↗ |
| Known as | NHS-IL12 | “PDS01ADC (previously referred to as NHS-IL12) is a novel antibody-drug conjugate designed to deliver the immunomodulatory cytokine interleukin-12 to areas of tumor necrosis and...” PMID 42365236 ↗ Jun 20261“PDS01ADC (NHS-IL12) is an immunocytokine composed of two IL-12 heterodimers, each fused to the H-chain of the NHS76 antibody.” NCT05361798 ↗ |
| Modality | Protein / enzyme biologic | “PDS01ADC is an immunocytokine composed of two interleukin (IL)-12 heterodimers, each fused to the H-chain of the NHS76 antibody.” NCT04235777 ↗ |
| Route | Subcutaneous | “An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT” NCT04235777 ↗ |